Powered by artificial intelligence, the new Ultrasound Workspace platform reportedly offers advanced echocardiography capabilities and facilitates enhanced diagnostic workflows.
In what may be a significant advance in echocardiography analysis and reporting across multiple systems, Philips launched the Ultrasound Workspace platform at the American College of Cardiology’s Annual Scientific Session and Expo (ACC 2022).
Combining 3D echocardiography capabilities with artificial intelligence (AI)-driven analysis and quantification tools, the Ultrasound Workspace also bolsters connectivity and reporting across different systems with vendor-neutral applications and remote browser access, according to Philips.
“We have combined the power of AI with deep clinical knowledge to create a solution that integrates into the workflows of healthcare providers to help drive efficient clinical decision-making,” noted Jeff Cohen, the senior vice president and global business leader of ultrasound for Philips. “With Ultrasound Workspace, our customers can experience a whole new world of echocardiography workflow to help improve both the patient and staff experience.”
Incorporating quality standards from the American Society of Echocardiography (ASE) and Intersocietal Accreditation Commission (IAC), Philips said the Ultrasound Workspace builds upon the capabilities of Philips’ ultrasound system EPIQ CV with improved efficiency and diagnostic confidence of quantitative measurements such as left ventricular ejection fraction.
Offering flexible licensing for facilities large and small, Philips noted that Ultrasound Workspace is a scalable platform that can be utilized as a stand-alone solution or incorporated into existing PACS and EMR echocardiography workflows.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.